Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171:388–416.
Kollef MH. Gram-negative bacterial resistance. Evolving patterns and treatment paradigms. Clin Infect Dis 2005;40:85–88.
Pitten FA, Panzig B, Schröder G, Tietze K, Kramer A. Transmission of a multiresistant Pseudomonas aeruginosa strain at a German university hospital 2001;47:125–130.
Bert F, Maubec E, Bruneau B, Berry P, Lambert-Zechovsky N. Multi-resistant Pseudomonas aeruginosa outbreak associated with contaminated tap water in a neurosurgery intensive care unit. J Hosp Infect 1998;39:53–62.
Ikematsu H, Yamaga S, Nabeshima A, Yamaji K, Kakuda K, Ueno K, et al. Incidence and duration of febrile episodes in a hospitalized geriatric cohort. J Jpn Assoc Infect Dis 1996;70:1079–1085.
Ikematsu H, Nabeshima A, Yamaga S, Yamaji K, Kakuda K, Ueno K, et al. Serum albumin level as a predictor of incidence of febrile episodes and mortality in hospitalized geriatric patients. J Jpn Assoc Infect Dis 1996;70:1259–1265.
Paramythiotou E, Lucet JC, Timsit JF, Vanjak D, Paugam-Burtz C. Acquisition of multidrug-resistant Pseudomonas aeruginosa in patients in intensive care units: role of antibiotics with antipseudomonal activity. Clin Infec Dis 2004;38:670–677.
Harris A, Torres-Viera C, Venkataraman L, DeGirolami P, Samore M, Carmeli Y. Epidemiology and clinical outcomes of patients with multiresistant Pseudomonas aeruginosa 1999;28:1128–1133.
Centers for disease control and prevention. National nosocomial infections surveillance (NNIS) system report, data summary from January 1992 to June 2001. Am J Infect Control 2001;29:404–421.
Hanberger H, Garcia-Rodriguez JA, Gobernado M, Goossens H, Nilsson LE, Struelens MJ. Antibiotics susceptibility among aerobic Gram-negative bacilli in intensive care units in 5 European countries. French and Portuguese ICU Study Groups, JAMA 1999;281:67–71.
Kollef MH. Appropriate empiric antimicrobial pneumonia: the role of the carbapenems. Respiratory Care 2004;49:1530–1541.
Kollef MH. Appropriate empirical antibacterial infections. Drugs 2003;63:2157–2168.
Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationalefor antibacterial dosing of mice and men. Clin Infect Dis 1998;26:1–12.
Kotapati S, Nicolau DP, Nightingale CH, Kuti JL. Clinical and economic benefits of meropenem dosage strategy based on pharmacodynamic concepts. Am J Health-Syst Pharm 2004;61:1264–1270.
Jaruratanasirikul S, Sriwiriyajan S. Comparison of the pharmacodynamics of meropenem in health volunteers following administration by intermittent infusion or bolus injection. J Antimicrob Chemother 2003;52:518–521.
Dandekar PK, Maglio D, Sutherland CA, Nightingale CH, Nicolau DP. Pharmacokinetics of meropenem 0.5 and 2 g every 8 hours as a 3-hour infusion. Pharmacotherapy 2003;23:988–991.
Mikamo H. The proper use of carbapenem examined by Monte Carlo simulation. Jpn J Antibiotics. 2005;58:359–367.
Kawano S, Matsushima T, Saito A, Nakata K, Yamaguchi K, Watanabe S, et al, editors. The JRS guidelines for the management of community-acquired pneumonia in adults. Tokyo: The Japanese Respiratory Society; 2007, p. 1–57.